P1-IMU-935-CRPC
Research type
Research Study
Full title
Dose escalation study to evaluate the safety, tolerability, and anti-tumor activity of single agent IMU-935 in patients with progressive, metastatic castration resistant prostate cancer
IRAS ID
301065
Contact name
Darius-Jean Namdjou
Contact email
Sponsor organisation
Immunic AG
Eudract number
2021-003090-59
Clinicaltrials.gov Identifier
Duration of Study in the UK
1 years, 10 months, 1 days
Research summary
Research Summary:
The purpose of this study is to test the safety, tolerability and anti-tumor activity of a study drug called IMU-935. In laboratory experiments, IMU-935 reduced the growth of prostate cancer cells. It is believed that this effect is produced due to inhibition of tumor cell proliferation and inhibition of immune cells supporting the tumor. This study is planned to test three different doses of IMU-935 to see which dose is the safest, best tolerable and most effective in participants with mCRPC. This will be the recommended dose to be tested in a final group of participants.Summary of Results:
The study results are published in NCT and shared with regulatory authorities. However they have not been reported in other websites, not published as articles in journals and not presented in any conference.REC name
South Central - Oxford B Research Ethics Committee
REC reference
21/SC/0293
Date of REC Opinion
26 Oct 2021
REC opinion
Further Information Favourable Opinion